Leaflong Therapeutics Unveils Innovative Digital Smoking Cessation Therapy at Cross-Strait Respiratory Disease Summit

From April 1 to 3, 2022, the “2022 Fifth Annual Academic Conference of the Respiratory Disease Professional Committee of the Cross-Strait Medical and Health Exchange Association and the Cross-Strait Summit Forum on Respiratory Diseases” was officially convened. Adhering to the principle of “New High-End, New Normal, New Brand,” the conference brought together nearly one hundred top experts and scholars from both sides of the Taiwan Strait and around the world to deliver professional reports and share insights, showcasing the latest research achievements in respiratory medicine across the two shores.

At the conference, Academician Zhong Nanshan, Director of Guangzhou National Laboratory and National Center for Respiratory Medicine, delivered a report titled “Characteristics of China’s COVID-19 Epidemic and Its Prevention and Control Measures,” elaborating on the current features of the COVID-19 epidemic in China and the corresponding prevention and control strategies. Academician Wang Chen, Vice President of the Chinese Academy of Engineering and President of Peking Union Medical College (PUMC) and the Chinese Academy of Medical Sciences (CAMS), presented an academic report on “Grand Medicine, Grand Public Health, and Grand Health.”

In the treatment of respiratory diseases, digital therapeutics, as an emerging therapeutic approach, has also attracted significant attention at this conference. As one of the outstanding pharmaceutical companies supporting the conference, Leaflong Therapeutics has been dedicated in recent years to the research, development, and production of digital therapeutic products for treating respiratory diseases. Taking its digital smoking cessation product, QuitIt, as an example, it provides a novel smoking cessation solution for patients with nicotine addiction.

At the expert academic session of the Tobacco Control Sub-venue, Langye Medical introduced China’s first digital therapeutic for tobacco control, co-developed with leading domestic experts in tobaccology. Built on a foundational technology framework of machine learning, big data, and intelligent sensors, and grounded in a robust evidence-based intervention system, this solution integrates outpatient care with personalized diagnosis and management of underlying chronic conditions and adverse reactions. It provides patients with nicotine addiction a scientific, efficient, and user-friendly digital therapeutic product to help them manage cravings effectively. This approach significantly improves patient adherence and treatment outcomes, delivering long-term benefits to patients suffering from chronic diseases associated with tobacco-related harm.

Langye Medical is a pioneer in digital patient management and therapies for tobacco-related diseases, dedicated to seamlessly integrating software and hardware engineering with biomedicine to create personalized, clinically validated next-generation treatment solutions for patients. Guided by a professional scientific advisory committee composed of leading domestic and international experts and working alongside algorithm engineers, the company continuously iterates and updates its products, explores new frontiers, and strives for superior and more refined medical approaches to help patients achieve healthier lives.